Minerva Neurosciences
NERV
71 hedge funds and large institutions have $205M invested in Minerva Neurosciences in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 11 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 20
0.82% more ownership
Funds ownership: 71% → 71.82% (+0.82%)
9% less funds holding
Funds holding: 78 → 71 (-7)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
29% less capital invested
Capital invested by funds: $290M → $205M (-$85.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.7M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$12.6M |
| 3 |
NC
Nexthera Capital
New York
|
+$2.57M |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$1.99M |
| 5 |
O
OrbiMed
New York
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$5.2M |
| 2 |
Millennium Management
New York
|
-$4.47M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.34M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.04M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.62M |
NERV Hedge Fund Activity: Q1 2017 in Review
71 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2017, worth a combined $205M — down 29% from $290M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NERV and 9 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.2M sold.
- 71 institutional investors held Minerva Neurosciences (NERV) as of Q1 2017, down from 78 in Q4 2016.
- Funds reported $205M of Minerva Neurosciences stock for Q1 2017, down 29% quarter-over-quarter.
- 9 funds opened new Minerva Neurosciences positions in Q1 2017 and 11 closed out, a net change of -2 holders.
- The largest Minerva Neurosciences buyer in Q1 2017 was BlackRock, an estimated $14.7M added.
- The largest Minerva Neurosciences seller in Q1 2017 was Marshall Wace, an estimated $5.2M sold.
Based on aggregated 13F filings for Q1 2017.